# Investment Thesis: Evaluating the Growth Trajectory of Dr. Agarwal's Eye Hospital

> This comprehensive analysis examines the operational strengths and strategic positioning of Dr. Agarwal's Eye Hospital (544350) within the competitive healthcare sector. The thesis evaluates the company's business model, management efficiency, and long-term growth potential to determine its risk-reward profile. By exploring various future scenarios, this report provides a detailed look at whether the hospital's expansion plans align with its current market valuation.

**Companies**: Dr Agarwal's Hea
**Sectors**: Healthcare
**Published**: 2026-03-31
**Last Updated**: 2026-03-31
**Source**: https://thesisloop.ai/thesis/acd751f7-2d00-475c-a019-0f1ebd25041c

## Score Overview

| Company | Management | Business Model | Future Growth | Risk |
|---------|-----------|---------------|--------------|------|
| Dr Agarwal's Hea | 73/100 | 66/100 | 70/100 | 56/100 |

## Dr Agarwal's Hea (BSE:544350)

**Sector**: Healthcare | **Industry**: Hospital

### Management Credibility

- **[CATALYST] Land Approval and Licensing Reform** (NEUTRAL): The company expects to obtain licenses and approvals for the new subsidiary facility by Q2 FY27.
  > is we are expecting to complete everything and get all our licenses and approvals by Q2
- **[CATALYST] M&A of Regional Hospital Chains** (POSITIVE, IN_PROGRESS): Management has formally approved and announced the merger of Dr. Agarwal’s Eye Hospital Limited (AEHL) into Dr. Agarwal’s Health Care Limited (AHCL), significantly ahead of the 3-year timeline initially suggested in June 2025.
  > The board of directors of AHCL & AEHL have approved the merger of AEHL with AHCL, creating a single listed entity housing the entirety of Dr . Agarwal’s operations
- **[METRIC] Bed Occupancy Rate** (NEUTRAL): Overall EBITDA margins for H2 FY26 are expected to remain at similar levels to H1 FY26 due to expansion pace.
  > But in terms of the overall margins with the pace of expansion and with more Greenfields getting launched, the overall margins on a percentage basis should be on similar levels as to whatever we have reported on for H1, Tushar
- **[METRIC] New Bed Maturity Timeline** (NEUTRAL): Management expects new facilities in non-core markets to reach breakeven within 15 to 18 months.
  > However, we expect the facilities to broadly breakeven around the 15 to 18
- **[PRINCIPLE] Brownfield Expansion Over Greenfield for ROE** (POSITIVE, MET): The company successfully relocated and upgraded its Whitefield, Bangalore facility in August 2024 from a secondary to a tertiary center, resulting in a 20% growth in revenue per month.
  > recording a growth of more than 20% since we have relocated to this new 20,000
- **[PRINCIPLE] Case Mix Determines ARPOB Trajectory** (NEUTRAL): Expectation of 4.5% to 5% growth in realization due to premiumization in cataract surgeries.
  > We are seeing a good amount of increase in premiumization, and that has been around 4.5% to 5% for this quarter. We hope to continue with that kind of growth over the next few quarters
- **[PRINCIPLE] Doctor Ecosystem Is Competitive Moat** (NEUTRAL): Management is focused on attracting and retaining a qualified team of medical professionals through research opportunities and a robust career development program.
  > Talent ✓ Continuous Learning and Research Opportunities for Doctors ✓ Strong Network Effects from Robust Career Development Program
- **[PRINCIPLE] Occupancy Is Primary Margin Lever** (NEUTRAL): Management intends to selectively relocate mature facilities to cater to high demand areas.
  > Selective relocation of mature facilities to cater to high demand
- **[TREND] Massive Capacity Addition Cycle** (POSITIVE, IN_PROGRESS): The company has added 25 facilities in the first three quarters of FY26 (11 in Q2 and 14 in Q3). To meet the H2 target of 30, they need 16 more in Q4, which is exactly what they have guided for.
  > Added 13 facilities in Q1’FY26 , 11 facilities in Q2’FY26 and 14 facilities in Q3’FY26
- **[TREND] Robotic and Minimally Invasive Surgery** (NEUTRAL): The company is expanding its advanced surgical capabilities by adding robotic systems in Gurgaon and Vashi.
  > Additionally, we are strengthening our advanced surgical capabilities with the addition of robotic systems in Gurgaon
- **[TREND] Tier-2/3 City Hospital Expansion** (NEUTRAL): The company plans to significantly expand its presence in the Delhi-NCR market over the next 12 months.
  > Building on this momentum, we plan to significantly expand our presence rapidly in the Delhi-NCR market over the next 12 months
- The cash flow statement for the subsidiary (AEHL) confirms the receipt of INR 70 Cr. from the issue of equity share capital during H1 FY26. (POSITIVE, MET)
  > Proceeds from issue of equity share capital (including employee stock options

### Business Model

- **[CATALYST] NABH Accreditation as Quality Differentiator** (NEUTRAL): The company holds a quality moat by having the highest number of NABH accredited facilities among eye care players in India, which is a key differentiator for insurance and patient trust.
  > Highest Number of NABH Accredited Facilities Amongst Eye Care Players in India
- **[METRIC] International Patient Revenue Mix** (NEGATIVE, Change: CONTRACTING): International revenue share has contracted slightly as domestic growth outpaces Africa, which faced headwinds from currency impacts and flattish growth.
  > But in Africa, it was flattish. And in fact, a few of the facilities had slight de- growth as well due to currency impact
- **[PRINCIPLE] Case Mix Determines ARPOB Trajectory** (POSITIVE, Change: EXPANDING): Surgical revenues remain the dominant pillar, with volumes growing 28% year-on-year for the full year. High-end cataract surgeries increased their contribution to the mix.
  > in FY '25, the surgical revenues form the main pillar of our service offering, contributing to
- **[TREND] Massive Capacity Addition Cycle** (POSITIVE, Change: EXPANDING): The company is aggressively expanding its footprint, adding 59 facilities in FY25 and targeting another 55-60 in FY26, with a focus on the southern states and Maharashtra.
  > Looking ahead, in FY '26, we are targeting a launch of 55 to 60 facilities
- **[TREND] Robotic and Minimally Invasive Surgery** (POSITIVE, Change: EXPANDING): Adoption of high-end technology is accelerating, specifically in laser cataract (Femto) and refractive surgery (SMILE), which is driving premiumization.
  > increase in contribution coming in from high-end cataract surgeries, which has moved up from 19
- **[TREND] Tier-2/3 City Hospital Expansion** (POSITIVE, Change: EXPANDING): The revenue contribution from India has increased as the company focuses on domestic expansion, particularly in Tier 2 and Tier 3 cities.
  > There has been greater focus on India, with its contribution to the overall group revenue increasing from 87.2% in FY '24 to 89.9% in FY '25. Revenue from operations in India for FY '25 totaled INR1538 crores, marking a growth of 32.3% year-on-year
- Revenue from opticals and pharmaceuticals grew 27.5% but its share of the total revenue mix remained stable at approximately 20.8%. (NEGATIVE, Change: CONTRACTING)
  > Opticals, Contact Lens, and Accessories & Pharmaceutical Products 20.8%

### Future Growth

- **[PRINCIPLE] Case Mix Determines ARPOB Trajectory** (POSITIVE, Trend: ACCELERATING): Refractive surgery (vision correction) is showing explosive growth, significantly outpacing the core cataract segment.
  > We have also seen an uptick in the refractive surgery segment, where we witnessed a 44% overall growth in the number of surgeries, and we have done 15,989 refractive surgeries in the year FY '25
- **[PRINCIPLE] Doctor Ecosystem Is Competitive Moat** (NEUTRAL): The company is building a 'Doctor Flywheel' by rapidly hiring and retaining specialists, which acts as a competitive moat in the healthcare industry.
  > 908 Doctors and 2,052 Paramedical Staff
- **[TREND] Massive Capacity Addition Cycle** (POSITIVE, Trend: ACCELERATING): The company is maintaining a steady, aggressive expansion pace, adding 59 facilities in FY25 and targeting another 55-60 in FY26.
  > Looking ahead, in FY '26, we are targeting a launch of 55 to 60 facilities
- **[TREND] Robotic and Minimally Invasive Surgery** (POSITIVE, Trend: ACCELERATING): The adoption of high-end laser-assisted (Femto) cataract surgeries is accelerating, with contribution to total cataract volume rising from 19.2% in FY24 to 22.5% in FY25.
  > increase in contribution coming in from high-end cataract surgeries, which has moved up from 19.2% in FY '24 to 22.5% in FY '25
- **[TREND] Tier-2/3 City Hospital Expansion** (POSITIVE, Trend: ACCELERATING): The geographic expansion is accelerating, particularly in North and West India, moving away from a South-only concentration.
  > 30.6% CAGR Growth in Total Facilities over FY2022 – FY2025
- Full-year PAT grew 16% to INR 110 crores, but management is projecting a significant acceleration to 35%+ growth for FY26. (POSITIVE, Trend: ACCELERATING)
  > Our profit after tax stood at INR110 crores, reflecting a 16% year-on-year growth

### Risk Assessment

- **[METRIC] International Patient Revenue Mix** (NEUTRAL, Risk: LOW): The international revenue contribution remains stable at 10.1% of total revenue. The company operates 18 facilities across nine African countries, maintaining a consistent footprint.
  > We commenced operations in Africa in 2012 and have since expanded to 18 facilities across nine
- **[METRIC] New Bed Maturity Timeline** (NEGATIVE, Risk: MODERATE): The risk is intensifying as the company plans to accelerate expansion to 55-60 new facilities in FY26 (up from 59 in FY25), with a significant capex of INR 310 crores.
  > Looking ahead, in FY '26, we are targeting a launch of 55 to 60 facilities
- **[PRINCIPLE] Brownfield Expansion Over Greenfield for ROE** (NEUTRAL, Risk: MODERATE): Management expects EBITDA margins to remain stable despite ongoing greenfield investments, but the sheer volume of new openings (55-60) keeps this risk elevated.
  > We expect our EBITDA margin to remain stable as ongoing greenfield investments continue to impact profitability
- **[PRINCIPLE] Doctor Ecosystem Is Competitive Moat** (NEUTRAL, Risk: MODERATE): Manpower costs grew by 28.4% YoY, exactly in line with revenue growth (28.4%), suggesting costs are currently being managed but remain a high-growth expense item.
  > Manpower costs for the year totaled INR574 crores, up by 28.4% compared to last year. This was driven by strategic hiring and increase in our workforce due to addition of new facilities
- **[TREND] Massive Capacity Addition Cycle** (NEGATIVE, Risk: MODERATE): The company continues a rapid expansion cycle, growing total facilities at a 29.7% CAGR from FY22 to Q1 FY26. While this drives revenue, it maintains pressure on margins as new centers ramp up.
  > 29.7% CAGR Growth in Total Facilities over FY22 – Q1FY26
- **[TREND] Tier-2/3 City Hospital Expansion** (NEGATIVE, Risk: HIGH): Geographic concentration remains high but is gradually diversifying. Revenue from the South region decreased from 64% to 63.1% of the payor mix, and the company is aggressively expanding into the North (Delhi NCR, Punjab) and West (Gujarat).
  > Approximately 65% of our Indian network is present in cities beyond the top metropolitan areas
- Execution risk remains high as the company added 59 new facilities in FY25. The EBITDA margin saw a slight decline from 29.5% in FY24 to 28.6% in FY25 due to the ramp-up of these new centers. (NEGATIVE, Risk: MODERATE)
  > We added 59 new facilities this year

### Scenario Analysis

- The company is scaling its 'Hub and Spoke' model, which relies on digital connectivity and automated workflows to manage 208 spoke facilities. This infrastructure is being used to strengthen diagnosis capabilities and surgical outcomes through specialized equipment. (POSITIVE)
  > we have built a network of over 236 facilities which includes 28 hubs and 208 spokes
- The company's exposure to geopolitical risks in Africa remains stable but significant. Management reported that 8% of their centers are located internationally in Africa (Page 3). While they faced 'headwinds' in Africa due to currency impact (Page 8), they have not yet reported direct supply chain disruptions from the Iran/Red Sea conflict, though they remain geographically exposed to these trade routes for equipment and consumables. (NEGATIVE)
  > 8% of our centers are located internationally in the continent of Africa

---
*Generated by [ThesisLoop](https://thesisloop.ai) — AI investment research for Indian equities.*